252 related articles for article (PubMed ID: 32670598)
1. Protocol for Take-home naloxone In Multicentre Emergency (TIME) settings: feasibility study.
Jones M; Bell F; Benger J; Black S; Buykx P; Dixon S; Driscoll T; Evans B; Edwards A; Fuller G; Goodacre S; Hoskins R; Hughes J; John A; Jones J; Moore C; Sampson F; Watkins A; Snooks H
Pilot Feasibility Stud; 2020; 6():96. PubMed ID: 32670598
[TBL] [Abstract][Full Text] [Related]
2. Is a randomised controlled trial of take home naloxone distributed in emergency settings likely to be feasible and acceptable? Findings from a UK qualitative study exploring perspectives of people who use opioids and emergency services staff.
Sampson FC; Hughes J; Long J; Buykx P; Goodacre SW; Snooks H; Edwards A; Evans B; Jones J; Moore C; Johnston S
BMC Emerg Med; 2024 Apr; 24(1):75. PubMed ID: 38679713
[TBL] [Abstract][Full Text] [Related]
3. Paramedic-supplied 'Take Home' Naloxone: protocol for cluster randomised feasibility study.
Moore C; Lloyd G; Oretti R; Russell I; Snooks H
BMJ Open; 2014 Mar; 4(3):e004712. PubMed ID: 24650810
[TBL] [Abstract][Full Text] [Related]
4. A study protocol for a European, mixed methods, prospective, cohort study of the effectiveness of naloxone administration by community members, in reversing opioid overdose: NalPORS.
Metrebian N; Carter B; Eide D; McDonald R; Neale J; Parkin S; Dascal T; Mackie C; Day E; Guterstam J; Horsburgh K; Kåberg M; Kelleher M; Smith J; Thiesen H; Strang J
BMC Public Health; 2023 Aug; 23(1):1608. PubMed ID: 37612698
[TBL] [Abstract][Full Text] [Related]
5. Patient characteristics associated with being offered take home naloxone in a busy, urban emergency department: a retrospective chart review.
O'Brien DC; Dabbs D; Dong K; Veugelers PJ; Hyshka E
BMC Health Serv Res; 2019 Sep; 19(1):632. PubMed ID: 31488142
[TBL] [Abstract][Full Text] [Related]
6. Overdose and take-home naloxone in emergency settings: A pilot study examining feasibility of delivering brief interventions addressing overdose prevention with 'take-home naloxone' in emergency departments.
Black E; Monds LA; Chan B; Brett J; Hutton JE; Acheson L; Penm J; Harding S; Strumpman D; Demirkol A; Lintzeris N
Emerg Med Australas; 2022 Aug; 34(4):509-518. PubMed ID: 35021268
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the impact of a national naloxone programme on ambulance attendance at overdose incidents: a controlled time-series analysis.
McAuley A; Bouttell J; Barnsdale L; Mackay D; Lewsey J; Hunter C; Robinson M
Addiction; 2017 Feb; 112(2):301-308. PubMed ID: 27614084
[TBL] [Abstract][Full Text] [Related]
8. Retrospective analysis of patterns of opioid overdose and interventions delivered at a tertiary hospital emergency department: impact of COVID-19.
Potaka KL; Freeman R; Soo D; Nguyen NA; Sim TF; Moullin JC
BMC Emerg Med; 2022 Apr; 22(1):62. PubMed ID: 35397487
[TBL] [Abstract][Full Text] [Related]
9. Designing, implementing and evaluating the overdose response with take-home naloxone model of care: An evaluation of client outcomes and perspectives.
Lintzeris N; Monds LA; Bravo M; Read P; Harrod ME; Gilliver R; Wood W; Nielsen S; Dietze PM; Lenton S; Shanahan M; Jauncey M; Jefferies M; Hazelwood S; Dunlop AJ; Greenaway M; Haber P; Ezard N; Malcom A
Drug Alcohol Rev; 2020 Jan; 39(1):55-65. PubMed ID: 31774221
[TBL] [Abstract][Full Text] [Related]
10. Distribution of take-home opioid antagonist kits during a synthetic opioid epidemic in British Columbia, Canada: a modelling study.
Irvine MA; Buxton JA; Otterstatter M; Balshaw R; Gustafson R; Tyndall M; Kendall P; Kerr T; Gilbert M; Coombs D
Lancet Public Health; 2018 May; 3(5):e218-e225. PubMed ID: 29678561
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with take-home naloxone kit usage in British Columbia: an analysis of administrative data.
Lei V; Ferguson M; Geiger R; Williams S; Liu L; Buxton JA
Subst Abuse Treat Prev Policy; 2022 Mar; 17(1):25. PubMed ID: 35361228
[TBL] [Abstract][Full Text] [Related]
12. Do electronic health record prompts increase take-home naloxone administration for emergency department patients after an opioid overdose?
Marino R; Landau A; Lynch M; Callaway C; Suffoletto B
Addiction; 2019 Sep; 114(9):1575-1581. PubMed ID: 31013394
[TBL] [Abstract][Full Text] [Related]
13. Yes, not now, or never: an analysis of reasons for refusing or accepting emergency department-based take-home naloxone.
Kestler A; Giesler A; Buxton J; Meckling G; Lee M; Hunte G; Wilkins J; Marks D; Scheuermeyer F
CJEM; 2019 Mar; 21(2):226-234. PubMed ID: 29789030
[TBL] [Abstract][Full Text] [Related]
14. Twenty years of take-home naloxone for the prevention of overdose deaths from heroin and other opioids-Conception and maturation.
McDonald R; Campbell ND; Strang J
Drug Alcohol Depend; 2017 Sep; 178():176-187. PubMed ID: 28654870
[TBL] [Abstract][Full Text] [Related]
15. Development of a take-home naloxone program at an urban academic emergency department.
Eswaran V; Allen KC; Cruz DS; Lank PM; McCarthy DM; Kim HS
J Am Pharm Assoc (2003); 2020; 60(6):e324-e331. PubMed ID: 32690447
[TBL] [Abstract][Full Text] [Related]
16. Take-Home Naloxone Kits: Attitudes and Likelihood-Of-Use Outcomes from a European Survey of Potential Overdose Witnesses.
McDonald R; Breidahl S; Abel-Ollo K; Akhtar S; Clausen T; Day E; Kelleher M; McAuley A; Petersen H; Sefranek M; Thiesen H; Strang J
Eur Addict Res; 2022; 28(3):220-225. PubMed ID: 35114666
[TBL] [Abstract][Full Text] [Related]
17. Take-home naloxone programs for suspected opioid overdose in community settings: a scoping umbrella review.
Moustaqim-Barrette A; Dhillon D; Ng J; Sundvick K; Ali F; Elton-Marshall T; Leece P; Rittenbach K; Ferguson M; Buxton JA
BMC Public Health; 2021 Mar; 21(1):597. PubMed ID: 33771150
[TBL] [Abstract][Full Text] [Related]
18. Design details for overdose education and take-home naloxone kits: Codesign with family medicine, emergency department, addictions medicine and community.
Sellen K; Goso N; Halleran L; Mulvale-Fletcher A; Sarmiento F; Ligabue F; Handford C; Klaiman M; Milos G; Wright A; Charles M; Sniderman R; Hunt R; Parsons JA; Leece P; Hopkins S; Shahin R; Jüni P; Morrison L; Campbell DM; Strike C; Orkin A;
Health Expect; 2022 Oct; 25(5):2440-2452. PubMed ID: 35909312
[TBL] [Abstract][Full Text] [Related]
19. A systematic review of the distribution of take-home naloxone in low- and middle-income countries and barriers to the implementation of take-home naloxone programs.
Sajwani HS; Williams AV
Harm Reduct J; 2022 Oct; 19(1):117. PubMed ID: 36266701
[TBL] [Abstract][Full Text] [Related]
20. Protocol for a mixed-methods feasibility study for the surviving opioid overdose with naloxone education and resuscitation (SOONER) randomised control trial.
Orkin A; Campbell D; Handford C; Hopkins S; Klaiman M; Leece P; Parsons JA; Shahin R; Strike C; Thorpe K; Sellen K; Milos G; Wright A; Charles M; Sniderman R; Morrison L;
BMJ Open; 2019 Nov; 9(11):e029436. PubMed ID: 31722937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
